Niki BioSolutions Stock (NASDAQ:NIKI)

Financials Chart

Previous Close

$2.22

52W Range

$1.94 - $172.00

50D Avg

$5.96

200D Avg

$8.14

Market Cap

$165.32K

Avg Vol (3M)

$158.58K

Beta

0.17

Div Yield

-

NIKI Company Profile

Niki BioSolutions is a biopharmaceutical company that resulted from the merger of Aptorum Group and DiamiR Biosciences. The company focuses on developing and commercializing a diverse portfolio of therapeutic and diagnostic assets. Its work spans from treatments for diseases with unmet medical needs, particularly in oncology and infectious diseases, to the development of innovative, blood-based diagnostic tests for brain health and other conditions.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

1

IPO Date

Jul 20, 2026

Website

NIKI Performance

NIKI Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	$431.38K
Operating Income	$-1.82M	$-3.80M	$-10.60M
Net Income	$-1.36M	$-4.27M	$-2.83M
EBITDA	$-1.82M	$-3.76M	$-9.48M
Basic EPS	$-1.90	$-7.80	$-6.20
Diluted EPS	$-1.90	$-7.80	$-6.20

Fiscal year ends in Dec 25 | Currency in USD